Sign inJoin free

Watch / CEOs & MDs

Recce Pharmaceuticals (REC) shares surge on positive trial update

8 Dec 20214:45

Recce Pharmaceuticals (REC) shares surge on positive trial update

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Recce Pharmaceuticals (REC) shares have marched higher this week on the back of a positive trial update, which revealed its anti infective drug showed a visible reduction in burn wound infections. Recce's trial broad spectrum antibiotics seek to address the problem of drug resistant bacteria. Recce CEO James Graham says Professor Fiona Wood and her team at Fiona Stanley Hospital in Perth are assessing the safety and efficacy of its lead compound R 327 in patients with infected burn wounds under the trial. He says they have reported positive results to date on a small number of patients. James says Recce is very well funded to continue with clinical trials of this and other broad spectrum antibiotics it has in its pipeline of development.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy